Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized controlled trial of ARQ 197 in unresectable hepatocellular carcinoma after failure of one prior systemic therapy
2008-007155-27Phase 2Completed
- Sponsor
- ArQule
- Start
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing ARQ 197 with Placebo (2 arms). Primary endpoint: Time to progression. Started Aug 2009; status: completed.
02
Drugs
tivantinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2008-007155-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007155-27.